Welcome to our new website
As well as being able to load content faster than ever before, you'll now find it's much easier to find all the content you need about the Asian business world.
Health Technology
Shionogi & Co., Ltd.
- 6,189.00 JPY
- +40.00
- +0.65%
Japan
Aug 20, 2018Ticker
TKS(4507)Prev. close
6,149Market cap (JPY)
1,993.11BMarket cap (USD)
18,044.57MShares
324.13M
In the news
- Single-dose flu drug approved for sale in Japan Feb 23, 2018
- Takeda Pharma buying Belgian startup TiGenix for $626m Jan 6, 2018
- Pharmaceutical maker Shionogi tapping AI to speed drug development Jan 5, 2018
- Chugai Pharma eyes sale of generics operations to Taiyo Nov 14, 2017
- Mitsubishi Tanabe to buy Israeli bioventure for $1.1bn Jul 25, 2017 See more articles on Shionogi & Co., Ltd.
Business Summary
Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.
Financial Highlights
| Mar 2018 | JPY | USD |
| Revenue | 344,667M | 3,109.80M |
| Gross Profit | 270,756M | 2,442.93M |
| Operating income | 115,219M | 1,039.57M |
| Income before tax | 137,378M | 1,239.51M |
| Net income | 108,866M | 982.25M |
| EBITDA | 134,226M | 1,211.07M |
| Diluted EPS | 337.43 | 3.04 |
| Dividends Per Share | 82 | 0.73 |
| Total Assets | 722,500M | 6,793.60M |
| Total liabilities | 117,656M | 1,106.30M |
| Total equity | 601,374M | 5,654.66M |
| Operating cash flow | 129,790M | 1,171.04M |
| Currency in JPY | Currency in USD |
Historical Data
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | |
| Revenue | 289,717M | 273,991M | 309,973M | 338,890M | 344,667M |
| Gross Profit | 211,724M | 191,802M | 235,215M | 261,113M | 270,756M |
| Operating income | 63,556M | 50,365M | 91,406M | 108,179M | 115,219M |
| Income before tax | 64,869M | 82,051M | 97,452M | 122,695M | 137,378M |
| Net income | 41,831M | 44,060M | 66,687M | 83,878M | 108,866M |
| EBITDA | 79,182M | 66,016M | 107,275M | 124,519M | 134,226M |
| Diluted EPS | 124.85 | 132.04 | 201.70 | 255.87 | 337.43 |
| Dividends Per Share | 46 | 52 | 62 | 72 | 82 |
| Total Assets | 584,803M | 602,900M | 639,638M | 670,271M | 722,500M |
| Total liabilities | 112,391M | 124,017M | 125,761M | 144,058M | 117,656M |
| Total equity | 468,650M | 474,530M | 509,792M | 522,737M | 601,374M |
| Operating cash flow | 79,496M | 45,604M | 102,290M | 111,903M | 129,790M |
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | |
| Revenue | 2,892.20M | 2,494.08M | 2,581.29M | 3,129.53M | 3,109.80M |
| Gross Profit | 2,113.61M | 1,745.93M | 1,958.74M | 2,411.29M | 2,442.93M |
| Operating income | 634.47M | 458.46M | 761.18M | 998.99M | 1,039.57M |
| Income before tax | 647.57M | 746.89M | 811.52M | 1,133.04M | 1,239.51M |
| Net income | 417.59M | 401.06M | 555.33M | 774.58M | 982.25M |
| EBITDA | 790.46M | 600.92M | 893.33M | 1,149.89M | 1,211.07M |
| Diluted EPS | 1.24 | 1.20 | 1.67 | 2.36 | 3.04 |
| Dividends Per Share | 0.45 | 0.47 | 0.51 | 0.66 | 0.73 |
| Total Assets | 5,678.52M | 5,027.30M | 5,690.98M | 6,015.17M | 6,793.60M |
| Total liabilities | 1,091.33M | 1,034.12M | 1,118.91M | 1,292.81M | 1,106.30M |
| Total equity | 4,550.66M | 3,956.88M | 4,535.71M | 4,691.16M | 5,654.66M |
| Operating cash flow | 793.59M | 415.12M | 851.81M | 1,033.38M | 1,171.04M |
Valuation Measures
| Mar 2018 | |
| PER | 16.02 |
| ROA | 15.63% |
| ROE | 19.36% |
| Operating margin | 33.42% |
| Profit margin | 31.58% |
Key executives
- President & Representative Director: Isao Teshirogi
- Manager-Accounting & Finance: Kohji Hanasaki
- Director & Vice President: Takuko Sawada
- Executive Officer: Masaaki Takeyasu
- Executive Officer & Personnel Manager: Noriyuki Kishida
Shareholders
- Sumitomo Life Insurance Co. (5.7%)
- Nomura Asset Management Co., Ltd. (5.4%)
- Wellington Management Co. LLP (4.2%)
- Asset Management One Co., Ltd. (4.1%)
- BlackRock Fund Advisors (3.2%)
- Shionogi & Co., Ltd. (3.0%)
- Sumitomo Mitsui Banking Pension Fund (2.9%)
- Nikko Asset Management Co., Ltd. (2.8%)
- Nippon Life Insurance Co. (2.5%)
- Daiwa Asset Management Co. Ltd. (2.2%)
Contact Details
- Website:http://www.shionogi.co.jp
- Address: 3-1-8 Dosho-machi, Chuo-Ku, Osaka, 541-0045, Japan
- Phone: +81.6.6202.2161
Related Companies
- Shionogi & Co. Restricted Stock Compensation Plan
- Shionogi Healthcare & Co. Ltd.
- Shionogi USA Holdings, Inc.
- Beijing Shionogi Pharmaceutical Technology Ltd.
- Shionogi Ltd.
- Ezose Sciences, Inc.
- Shionogi, Inc.
- Shionogi Institute for Medical Science
- Aburahi Laboratories
- Taiwan Shionogi & Co. Ltd.
- Shionogi Pharma Chemicals Co., Ltd.
- Shionogi General Service Co., Ltd.
- Shionogi Bunseki Center KK
- Shionogi Ireland Ltd.
- Shionogi Engineering Service Co. Ltd.
- Shionogi Bioresearch Corp.
- Shionogi & Co. Ltd. Pension Fund
- Daiwa Trading Co., Ltd.
- Soei Co., Ltd.
- Tall Bridge, Inc.
- C&O Pharmaceutical Technology (Holdings) Ltd.
- QuatRx Pharmaceuticals Company
- Shionogi Pharma, Inc.
Competitors
- Gilead Sciences, Inc.
- KemPharm, Inc.
- TaiMed Biologics Inc.
- Achaogen, Inc.
- aTyr Pharma, Inc.
- Iterum Therapeutics Plc
- Tetraphase Pharmaceuticals, Inc.
- Dova Pharmaceuticals, Inc.
- Spero Therapeutics, Inc.
- Acura Pharmaceuticals, Inc.
- Biohaven Pharmaceutical Holding Company Ltd.
- Microbio Co., Ltd.
- Nektar Therapeutics
- Humanigen Inc
- Progenics Pharmaceuticals, Inc.
Copyright © 2018 FactSet Research Systems Inc. All rights reserved.
Last Updated on 20 Aug, 2018You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month
You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month
Your full access to the Nikkei Asian Review has expired
